HMET-Forte Tablet SR contains Metformin 1000 mg as the active ingredient and is formulated as a sustained-release (SR) tablet to improve glycemic control in patients with type 2 diabetes mellitus. Metformin is a biguanide antihyperglycemic agent that primarily acts by decreasing hepatic glucose production, decreasing intestinal absorption of glucose, and improving insulin sensitivity by increasing peripheral glucose uptake and utilization. HMET-Forte Tablet SR is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, particularly in overweight patients or those with insulin resistance. The sustained-release formulation allows for once-daily dosing, enhancing patient compliance by minimizing gastrointestinal side effects commonly associated with immediate-release metformin. Common adverse effects include gastrointestinal disturbances such as nausea, vomiting, diarrhea, abdominal discomfort, and a metallic taste, which often diminish with continued use. Rare but serious adverse effects include lactic acidosis, especially in patients with renal impairment, hepatic dysfunction, or conditions predisposing to hypoxia. HMET-Forte Tablet SR should be used with caution in patients with renal or hepatic impairment, and renal function should be monitored regularly. It is contraindicated in patients with known hypersensitivity to metformin, acute or chronic metabolic acidosis, and should be temporarily discontinued during radiologic studies involving iodinated contrast media.